Pascal Soriot heroically defended the company against Pfizer, but now he needs to calm his investors
It’s hard to keep AstraZeneca out of the headlines. A booming share price made the company the biggest in the FTSE 100 index last month, albeit Shell is now marginally in front again. More significantly, the group is in the vanguard of Covid-fighting efforts by helping Oxford University develop a vaccine and then, we hope, produce a successful product in massive volumes.
Now, though, comes something different: a Bloomberg report of an approach last month to Gilead of the US to create a new pharma giant. Nobody expects a deal to happen, it should be said. The proposal, if that’s what it was, seems to have been tentative and no talks are in progress now.
